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Survivors of breast and other cancers often report protracted difficulty in performing tasks 
involving concentration and memory even years after the completion of adjuvant chemotherapy 
regimens. The current study investigated whether chemotherapy is associated with deficits in 
sensory gating and sensory memory. A group of nine breast cancer survivors, and nine age-
matched healthy control participants (mean age 54 years), watched silent films while pairs of 
clicks or streams of tones were presented during electroencephalographic recording. The 
survivors evinced a relatively weakened ability to inhibit redundant sensory stimulation (P50 
suppression), whether to the second of a pair of clicks or to a train of identical auditory tones. 
Dipole source analysis localized the survivors’ impairment to the hippocampus, with 
preservation of function in gating mechanisms of the frontal lobe and auditory cortex. Survivors 
also showed diminished sensory memory needed to register novel or deviant information in an 
otherwise uniform auditory environment (mismatch negativity). The findings suggest that 
chemotherapy is associated with a pervasive deterioration of early, automatic mechanisms of 
sensory gating. Loss of sensory inhibition may trigger a cascade of attention and memory deficits 
in survivors further down the information processing line, effectively accelerating cognitive 
aging through disruption of hippocampus-dependent memory functions. 
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Effects of Chemotherapy on Sensory Inhibition and Sensory Memory 
in Breast Cancer Survivors 
Introduction 
Although breast cancer is the most common form of cancer in women (excluding non-
melanoma skin cancer), and a leading cause of cancer death in America, the overall five-year 
survival rate is now an impressive 88% (Center for Disease Control and Prevention, 2010; 
American Cancer Society, 2010). Advances in clinical oncology have meant that more women 
than ever are living after chemotherapy. As the number of survivors increase, the ongoing 
treatment-related side effects must be addressed. Acute cognitive changes during chemotherapy 
are common (Vardy, Wefel, Ahles, Tannock, & Schagen, 2008; Wefel & Schagen, 2012), with a 
significant subgroup of cancer survivors revealing in self report protracted difficulty in 
performing certain cognitive tasks, months and even years after the completion of adjuvant 
chemotherapy regimens (Koppelmans et al., 2012; McLachlan, Devins, & Goodwin, 1998; 
Minisini et al., 2004; Reid-Arndt, 2006). Especially common are reports of impairments in 
concentration, maintaining performance speed, and remembering prospective chores (Berglund, 
Bolund, Fornander, Rutqvist, & Sjödén, 1991; Hedayati, Schedin, Nyman, Alinaghizadeh, & 
Albertsson, 2011), problems that often negatively impact employment after cancer treatment 
(Ahn et al., 2009; Bradley, Bednarek, & Neumark, 2002; Keith, Wu, Epp, & Sutherland, 2007; 
Munir, Burrows, Yarker, Kalawsky, & Bains, 2010). Survivors of breast cancer were among the 
first to report these symptoms and provide recurrent anecdotal evidence of “chemobrain.” 
Although the prevalence of neuropsychological deficits significantly decreases as time after the 
end of oncological therapy elapses, a subset of breast cancer survivors remains concerned about 
their prolonged deficits in memory and concentration abilities.  
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In 2003, researchers formed The International Cancer and Cognition Task Force to 
address the growing need for research into long-term cognitive impairments following 
chemotherapy in order to identify risk factors, treatment options, and preventive actions (Vardy 
et al., 2008). There has since been an upsurge in research on cognitive deficits following 
adjuvant chemotherapy, but there still remains a paucity of research into the underlying 
mechanisms of these purported cognitive deficits. 
In the last decade, systematic investigations on the effects of cancer and chemotherapy 
agents have begun to characterize the subset of survivors who, relative to healthy controls, 
display in tasks of selective attention and working memory persistent and clinically relevant 
long-term deficits (Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003; Stewart, 
Bielajew, Collins, Parkinson, & Tomiak, 2006), even as long as 20 years after treatment 
(Koppelmans et al., 2012). The study of cognitive decline following cancer therapy is 
complicated by the use of multiple treatments, side-effects such as cancer related fatigue, and 
psychiatric changes including depression and anxiety, along with mediators such as age, 
inflammation, sleep deprivation, and other medications. Figure 1 illustrates the constellation of 
factors that affect assessment of cognitive change. In addition, methodological confounds such as 
differences in patient populations, assessment instruments used, and criteria for defining change, 
complicate understanding of the incidence of post-treatment cognitive change and perhaps 
explain inconsistencies in reported prevalence (Ahles, 2012). Thus, despite more direct 
neuropsychological evidence from longitudinal studies of cancer patients before and after 
chemotherapy, results are inconsistent (Jenkins et al., 2006; Schagen, Muller, Boogerd, 
Mellenbergh, & van Dam, 2006; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004). Nevertheless, 
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a subset of survivors displays long-term post-treatment cognitive deficits independent of these 
confounds. 
Neuropsychological Evidence of Cancer-Related Cognitive Dysfunction 
 Approximately one in eight American women will be diagnosed with breast 
cancer in their lifetime (American Cancer Society, 2010). Treatment of breast cancer most often 
begins with surgery. Depending on diagnostic features, either a lumpectomy or a mastectomy is 
performed and surgery is completed with either sentinel (nearby) lymph node dissection or 
axillary (under armpit) lymph node dissection. Post-surgery, clinical criteria (such as age, cancer 
type, size, hormone receptor and metastatic status) establish a patient’s adjuvant treatment 
regimen, including chemotherapy, radiotherapy, endocrine treatment, and immunotherapy, by 
themselves or in combination with other treatments. Initial investigations of cancer-related 
cognitive decline focused on chemotherapy drugs and largely ignored the role these multi-
modality treatment strategies may have on cognitive function. Today, researchers are cognizant 
of the possible impact on cognition of cancer biology, chemotherapy, endocrine modulators, and 
psychological factors.  
Cancer Biology 
Wefel et al. (2004) conducted a small (n=18) prospective study of cognitive impairments 
before and after chemotherapy. Comprehensive neuropsychological evaluations of breast cancer 
patients, which included self-report measures of personality traits, affective status and 
carcinoma-specific quality of fife (QOL), were obtained three times over the course of their 
chemotherapy treatments: at baseline, three weeks after chemotherapy completion 
(approximately six months after baseline evaluations), and one year post-chemotherapy 
treatment. Using statistical approaches designed to minimize potential false positives while 
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maintaining the capacity to determine the frequency of actual impairment, Wefel et al. (2004) 
classified patients with a cognitive impairment at baseline and/or after treatment into two groups: 
those who had z-scores above 1.5 on two or more cognitive tests and those that had a z-score of 
2.0 on a single cognitive test.  
Unexpectedly, 33% of patients were classified as having cognitive impairment at 
baseline. Shortly after completing their cancer regimens, within-subject analyses revealed that 
61% of patients demonstrated cognitive decline from their baseline assessment in one or more 
cognitive tasks. Of these patients, approximately 50% remained cognitively impaired 18 months 
after initiation of adjuvant chemotherapy. Declines in performance occurred most often in the 
digit span and arithmetic subtests of the Wechsler Adult Intelligence Scale Revised (WAIS-R) 
and in the Trail-Making tests. Although these cognitive impairments were subtle, they were 
nonetheless associated with patients’ inability to return to work.   
Chemotherapy 
Early investigations of cognitive impairments in breast cancer survivors were cross-
sectional studies conducted on women receiving adjuvant chemotherapy after a primary 
diagnosis of breast cancer (Minisini et al., 2004). In a study of delayed chemobrain (nine years 
after the end of treatment), Ahles et al. (2002) found significant impairments in cognition and 
memory on neuropsychological tests. Cancer survivors receiving systemic chemotherapy were 
more likely to score in the lowest quartile on the Neuropsychological Performance Index (39% 
vs. 14%, P <.01). Treatment was associated with significantly impaired verbal memory (p<.01) 
and psychomotor functioning (p<.05).  
Schagen et al. (2006) conducted a prospective longitudinal study investigating the 
cognitive sequelae of chemotherapy using three groups of breast cancer patients and a control 
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group of healthy women. Two of the three breast cancer groups comprised high-risk breast 
cancer patients who had participated in a randomized trial receiving either high-dose adjuvant 
chemotherapy with cyclophosphamide, thiotTepa, and carboplatin (CTC “high dose” group) or 
standard-dose chemotherapy with 5- fluorouracil, epirubicin, and cyclophosphamide (FEC 
“standard” group), followed by radiotherapy and tamoxifen (40 mg daily for 2–5 years); the third 
breast cancer group consisted of women with Stage I breast cancer who received radiation 
treatments without systemic chemotherapy agents (no-CT “no chemo” group).  
Participants completed neuropsychological evaluations (10 tests, 24 indices) that 
measured cognitive functioning in five domains: focused–sustained attention, working–verbal–
visual memory, processing speed, executive function, and verbal/motor function. Premorbid 
intelligence was measured during the initial assessment using the Dutch Adult Reading test. 
Participants in the high-dose and standard-dose groups were tested before the start of 
chemotherapy and again six months after completion of therapy (~one year after initial 
evaluation). The “no chemo” group was re-assessed 12 months after their first assessment and 
the controls six months later.  
A patient was defined as cognitively impaired if she scored two standard deviations 
below the mean of the healthy group on at least three of the 24 test indices. Controlling for age 
and IQ, Schagen et al. (2006)found no significant differences among the four groups in 
neuropsychological test scores or in the percentage of participants who were classified as 
cognitively impaired at the first and second assessments. However, when the researchers 
accounted for age, IQ, practice and the magnitude of cognitive changes in test scores between 
assessments, they found that the percentage of breast cancer patients whose cognitive 
performance had deteriorated was significantly higher in the high-dose group (25%) - but not the 
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standard-dose group (12.8%) or no-chemo group (17.5%)  - relative to the control group (6.7%). 
Although the deterioration in cognitive performance over time occurred across a variety of tests 
measuring several cognitive functions, those most sensitive to executive functions exhibited the 
strongest effects. The results are consistent with accumulating research evidence that higher 
chemotherapy doses are linked with more severe and persistent cognitive impairment. This 
conclusion must be interpreted with caution, however, because the moderating role on cognitive 
decline of follow-up hormone replacement therapy is unknown in this study, since all 
participants in chemotherapy treatment received tamoxifen. 
Hormone Replacement Therapies 
Limitations of Schagen et al. (2006) suggest the effects of hormone replacement therapies 
(HRTs) such as tamoxifen and anastozole are especially relevant in discussions of chemobrain. 
These drugs, which prevent cancer growth in estrogen positive cancer tumors, belong to a class 
of compounds known as selective estrogen receptor modulators (SERMs). The use of SERMs in 
cancer treatments may contribute to cognitive decline after chemotherapy because of side effects, 
which include the induction of chemical menopause. Elderly women with low levels of unbound 
endogenous estradiol (a measure of available estrogen) are more likely than those with high 
levels to develop cognitive impairments (Yaffe et al., 2000). Menopausal symptoms such as hot 
flashes, symptoms of the normal aging process, occur more frequently, are more distressing, and 
are of greater duration in naturally and artificially postmenopausal breast cancer patients 
(Carpenter, Johnson, Wagner, & Andrykowski, 2002). In addition, patients who report more 
severe hot flashes endorse moderate to severe interference with sleep (40%), concentration 
(33%), mood (29%), and sexuality (28%). 
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 Jenkins, Shilling, Fallowfield, Howell, and Hutton (2004)gave a battery of 
neuropsychological tests to breast cancer patients enrolled in the anastrozole-tamoxifen-and-
combined (ATAC) trial for the treatment of breast cancer or post-menopausal healthy controls. 
Here, patients were assigned randomly into anastrozole alone, tamoxifen alone, or combined 
anastrozole and tamoxifen groups. Relative to healthy controls, breast cancer patients were found 
to be impaired on a processing speed task and a measure of immediate verbal working memory 
task. However, patient performance across groups was not significantly related to the length of 
hormone replacement therapy.  
Falleti et. al (2005) performed a meta-analysis of six cross-sectional breast cancer studies 
to investigate the effects of HRTs on six cognitive domains (attention, motor function, memory, 
language, executive function, and spatial ability). The meta-analysis revealed effect sizes of 
small to moderate magnitude in each domain: attention (.03) motor function (.51) memory (.26), 
language (.18) executive function (.41) spatial ability (.48). These findings suggest that HRTs 
may induce a generalized cognitive impairment. Moreover, a significant logarithmic relationship 
was found between effect size and time since last chemotherapy treatment (r
2
= .63) and between 
effect size and the percentage of patients currently taking tamoxifen (r
2
 = .60), and a linear 
relationship was found between effect size and average age (r
2
 = .67). These analyses indicate 
that the magnitude of impairment in cognitive function is larger in younger age groups. 
Interestingly, younger women with breast cancer commonly enter menopause artificially after 
surgery, chemotherapy, and or HRT. 
An open label, randomized study comparing the efficacy of exemestane versus tamoxifen 
treatments provided the opportunity to explore the effect of adjuvant endocrine treatments on 
cognitive functioning in post-menopausal breast cancer patients not treated with chemotherapy 
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(Schilder et al., 2010). Participants were patients in a exemestane group (n=99), a tamoxifen 
group (n=80), and a control group (i.e., healthy same-age female friends/relatives of patients 
included to account test-retest effects of neuropsychological tests; n=120). Comprehensive 
neuropsychological evaluations that included objective measures in cognitive abilities and self-
report measures of anxiety, depression, fatigue, menopausal symptoms, and cognitive 
functioning were conducted before surgery, before hormone therapy, and one year later. At 
follow-up, Schilder et al. (2010) found that tamoxifen, but not exemestane, was associated with 
worse performance in verbal memory, executive functioning, and information processing speed. 
In a later study, Schilder et al. (2012) found that patients report a lower frequency of cognitive 
failures than healthy controls, both before and after chemotherapy. The prevalence of cognitive 
complaints did not differ between the groups at initial testing, but over time, patients receiving 
tamoxifen reported more attention/concentration complaints than patients receiving exemestane. 
Although self-reported cognitive functioning showed moderate associations with 
anxiety/depression, fatigue, and menopausal complaints, it was not associated with actual 
cognitive test performance.  
Psychological Distress 
A breast cancer diagnosis interrupts an individual’s daily life and brings their mortality 
into focus (Saegrov & Halding, 2004). Typically, cancer diagnoses cause greater distress and 
trauma than other serious diseases and illnesses; it is a potential death sentence and a serious 
threat to one’s wellbeing. Despite the fact that the prognosis for breast cancer is generally quite 
good, breast cancer survivors must live with the ever-present threat of a relapse. In view of 
current knowledge regarding the links between emotion and cognition, stress induced by the 
cancer diagnosis may represent one source of cognitive impairment (Reid-Arndt & Cox, 2012). 
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Schilder et al. (2012) noted that many studies fail to find a relationship between 
subjective and objective measures of cognitive impairment following treatment for cancer 
(Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 2012). Psychological stress may be a 
reason: Perceived impairment may be an indicator of psychological distress rather than cognitive 
impairment (Hutchinson et al., 2012) or may increase vulnerability of breast cancer patients to 
cognitive impairment after chemotherapy (Vearncombe et al., 2009).  In fact, recent research 
suggests that psychological distress is significantly related to cognitive impairment in breast 
cancer patients (Ando-Tanabe et al., 2012; Antoni et al., 2012). Ando-Tanabe et al. (2012) found 
that chemotherapy patients had significantly lower baseline performance in digit symbol and 
verbal fluency relative to healthy controls, with task performance correlated negatively with 
anxiety. Since patients showed significantly higher anxiety at baseline, the authors proposed that 
anxiety could underlie the reported baseline impairments. 
Andreano, Waisman, Donley, and Cahill (2012) investigated the effect on cognitive 
dysfunction of glucocorticoid responses in survivors following long-term treatment of Lupron, a 
gonadotropin-releasing hormone agonist used in the treatment of estrogen receptor positive 
tumors. Glucocorticoid responses to a physiological stressor were not significant in Lupron-
treated survivors, but elevated cortisol levels in controls. Narrative recall was worse in survivors 
than controls, independent of stress treatment. Yet controls exposed to post-training stress 
showed significant enhancement of emotional recall and a significant relationship between 
cortisol release and subsequent memory, effects not observed in survivors. The results suggest 
that stress may contribute to cognitive difficulties in survivors by disrupting enhancement of 
memory. 
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Neurobiological Evidence of Cancer-Related Cognitive Dysfunction  
As clinical evidence of cancer-related cognitive loss accumulates, identification of the 
neural mechanisms at play in vulnerable patient subgroups becomes essential. Several candidate 
mechanisms have been suggested, but pinpointing the precise cause of cognitive loss following 
cancer treatment remains elusive (Ahles & Saykin, 2007; Seigers & Fardell, 2011). Viable 
molecular outcomes of chemotherapy include three primary mechanisms: (1) oxidative stress to 
DNA repair processes (Blasiak J. et al., 2004; Nadin, Vargas-Roig, Drago, Ibarra, & Ciocca, 
2006), (2) elevated levels of inflammatory cytokines in brain tissue (Burstein, 2007; Janelsins et 
al., 2012; Seigers & Fardell, 2011), and (3) genetic susceptibility to breakdowns in neural repair 
processes (Ahles et al., 2003). The brain is susceptible to oxidative stress due to its limited 
antioxidant capacity. Oxidative stress is created when excessive free radicals react with proteins, 
cell walls and DNA, causing damage to cell structures ultimately leading to cell death. 
Cancer tumors may indirectly disturb cognitive functioning through tissue release of 
cytokines and chemokines, regulatory molecules that foster communication among cells in the 
immune system (Ahles, 2012; Janelsins et al., 2012; Walker, Drew, Antoon, Kalueff, & 
Beckman, 2012). Abnormal concentrations of cytokines in neurodegenerative diseases, such as 
Alzheimer’s disease (AD), Parkinson’s disease, multiple sclerosis and traumatic brain injury, 
have been implicated in the pathogenesis of cognitive impairments (Janelsins et al., 2012). 
Recent literature suggests that elevated levels of cytokines and chemokines may play a role in 
cognitive deficits observed in chemobrain. For example, Janelsins et al. (2012) conducted an 
investigation of inflammatory processes by assessing the effects of two different chemotherapy 
regimens on cytokine IL-6 and chemokines MCP-1 and IL-8. They found significant differences 
in cognitive functioning between treatment regimens and significant negative correlations 
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between MCP-1 and the cognitive domains of concentration and forgetfulness for patients 
receiving adriamycin. Better-powered, longitudinal studies can in the future provide additional 
insight into cognitive sequelae following chemotherapy treatments by exploring the distinct 
inflammatory responses elicited by different chemotherapy regimens. 
Finally, genetic susceptibility to DNA damage may alter signaling pathways that act as 
master regulators of aging and thus control age-related brain pathology (Bishop, Lu, & Yankner, 
2010), thus contributing to the pathogenesis of chemotherapy-induced cognitive decline (Ahles, 
2012).  In particular, the epsilon 4 allele of APOE may be a potential genetic marker for 
increased vulnerability to chemotherapy-induced cognitive decline (Ahles et al., 2003). 
The three molecular candidates – oxidative stress, neuro-inflammation, and genetic 
susceptibility – in no way create an exhaustive list (Ahles, 2012; Ahles & Saykin, 2007; Seigers 
& Fardell, 2011; Walker et al., 2012). For example, it is conceivable that the concurrent 
administration of several cytotoxic agents could combine to have a negative synergistic effect on 
cognition. At present, though, there is insufficient clinical evidence to evaluate the relationships 
among types of chemotherapy regimens, dose intensities, and degree of cognitive impairment 
(Cheung, Chui, & Chan, 2012).  Thus, more research is needed to understand the role of 
pharmacological factors in chemotherapy-associated cognitive changes. 
Neurophysiological Evidence of Cancer-Related Cognitive Change 
The neurotoxic effects of chemotherapy agents target cells in the hippocampus (Dietrich, 
Han, Yang, Mayer-Proschel, & Noble, 2006; Seigers, Schagen, Beerling, et al., 2008) and 
prefrontal cortex (Ferguson, McDonald, Saykin, & Ahles, 2007; Hakamata, Matsuoka, Inagaki, 
et al., 2007; Inagaki, Yoshikawa, Matsuoka, et al., 2006), two brain regions critical to normal 
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memory and attentional functioning. However, emerging evidence indicates impairment may be 
more widespread than previously believed (Winocur et al., 2012). 
Animal Models  
Animal models can be utilized for systematic investigations into underlying physiological 
mechanisms of cognitive dysfunction in cancer (Seigers & Fardell, 2011). Animal models can be 
utilized for specific investigations into cause and effect relationship between drug treatments and 
cognition in breast cancer. Table 1 lists a summary of theses findings. Moreover, they have the 
potential to identify therapeutic targets to prevent and treat cognitive impairments. However, this 
method of inquiry is underutilized and only a few chemotherapeutic agents have been studied for 
their neurocognitive effects. 
Chemotherapy treatments in rodents are associated with increased cell death and 
decreased cell division in the dentate gyrus of the hippocampus, a region in which generation of 
new neurons continues into adult life, far beyond the point of neurogenesis in most other brain 
regions. These agents cause a dose-dependent negative effect on hippocampal cell proliferation 
and increase oxidative stress in the brain (ELBeltagy et al., 2012).  
Several animal reports have established a negative impact on hippocampus-dependent 
behaviors in learning and memory tasks of the chemotherapy drugs cyclophosphamide, 
methotrexate, methotrexate, 5-fluorouracil (5-FU), and thioTEPA (J. E. Fardell, Vardy, Logge, 
& Johnston, 2010; Joanna E. Fardell, Vardy, Shah, & Johnston, 2012; Wilson & Weber, 2013; 
Yang et al., 2012). Moreover, an investigation on cognitive function of two widely used 
cytotoxic agents -- cyclophosphamide and doxorubicin -- revealed disruption of hippocampal 
neurogenesis (Christie et al., 2012; Wilson & Weber, 2013). Here, rats that were chronically 
exposed to clinically relevant doses of chemotherapy drugs were impaired on the novel place 
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recognition (NPR) task and the contextual fear conditioning task (CFC). Both groups of 
chemotherapy treated rodents exhibited a significant decline (80%-90%) in hippocampal 
neurogenesis. Nevertheless, the functionality of hippocampal neurogenesis is still hotly debated 
(Seigers & Fardell, 2011). 
Imaging   
Studies utilizing functional and anatomical magnetic resonance imaging (MRI) and 
positron emission tomography (PET) have examined structural and functional changes in the 
brain associated with chemotherapy. Reduction in the volume of brain regions important for 
executive functioning (e.g., frontal cortex) and changes in the integrity of white matter tracks 
have been associated with changes in cognitive functioning in patients treated with 
chemotherapy (Saykin et al., 2003; Stemmer et al., 1994). Reduced activation in frontal cortex 
during a working memory task in patients treated with chemotherapy has also been reported 
(Saykin et al., 2006). A study using [O-15] PET demonstrated that breast cancer patients treated 
with chemotherapy showed decreased metabolic activity in the prefrontal cortex during short- 
and long-term memory tasks, relative to both breast cancer patients who did not receive 
chemotherapy and healthy controls (McDonald, Conroy, Ahles, West, & Saykin, 2010). 
McDonald, Conroy, Ahles, West, and Saykin (2012) reported evidence for compensatory 
activations in a prospective fMRI examination of brain alterations during a working memory task 
in breast cancer patients at baseline and one year after chemotherapy treatment. These results 
suggest that even before adjuvant treatment patients with breast cancer engage in compensatory 
hyperactivation of frontal cortices in response to the cancer disease process and raise the 
possibility that performance on neuropsychological testing may remain in the normal range 
through an altered activation of brain patterns. 




Few studies have sought to link chemotherapy treatment in humans to functional changes 
in electrophysiological (EEG) processing. One aim of the current study was to pinpoint 
electrophysiological correlates of breakdowns in specific cognitive processes in the aftermath of 
breast cancer treatment. Event-related potentials (ERPs), waveforms derived from EEG 
recordings time locked to individual stimuli and signal averaged across repeated trials, offer a 
noninvasive physiological measure of the time course and functional integrity of specific 
cognitive processes as a result of chemotherapy. Providing excellent resolution in the temporal 
domain, ERPs provide accurate voltage change in the millisecond range, and can help to 
distinguish and localize sequential stages of information processing in the brain. By comparison, 
PET and fMRI are considerably more sluggish in their temporal resolution, and are less cost 
efficient. ERPs provide independent measures of memory and information processing, two of the 
most commonly affected areas of cognitive functioning post-chemotherapy.  
Unfortunately, spatial resolution of ERPs is limited and very different source 
arrangements can lead to the same EEG measurements (Scherg & Von Cramon, 1986). This is 
known as the inverse problem. To address this problem, one must localize the supposed electric 
sources in the brain by introducing a priori assumptions on the generation of EEG signals 
(Michel et al., 2004). Advances in EEG analysis and computing capabilities have enabled spatial 
source reconstruction of ERP components. Michel et al. (2004) emphasized the important 
distinctions among different approaches of source reconstruction available in terms of their a 
priori constraints and assumptions and favor those that are heavily influenced by physiological 
principles over those that are influenced by the experimenter. In addition, the authors state that 
the more appropriate the assumptions the more trustworthy the source estimations.  
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P3b component. Several recent ERP studies suggest impairments from chemotherapy in 
the timing and/or efficiency of auditory memory and attentional processes. For example, 
Kreukels and her colleagues (Kreukels, Schagen, Ridderinkhof, et al., 2005, 2006; Kreukels, 
Hamburger, de Ruiter, et al., 2008; Kreukels, van Dam, Ridderinkhof, et al., 2008) have tested 
breast cancer survivors and control participants in auditory or visual oddball paradigms to 
measure the relative amplitude and latency of the P3b ERP component, which has neural sources 
in the posterior cingulate and parahippocampal gyrus (Halgren, Baudena, Clarke, Heit, Liegeois, 
et al., 1995; Halgren et al., 1998; Knight, Scabini, Woods, & Clayworth, 1989).  
In one study, Kruekels, Hamburger, de Ruiter et al. (2008) compared survivors who had 
undergone different chemotherapy regimens (i.e., FEC and CTC) with Stage I breast cancer 
patients who had not received chemotherapy (control). Auditory P3b amplitude and latency were 
reduced in each of the chemotherapy groups relative to controls, with no concomitant effect of 
tamoxifen treatment. The authors additionally found that chemotherapy had no effect on the 
earlier N1 ERP component, a measure of perceptual integrity. The results suggest that 
chemotherapy undermines the speed and distinctiveness of stimulus encoding in working 
memory, leaving mechanisms of perceptual encoding intact.  
SENSORY INHIBITION AND MEMORY AFTER BREAST CANCER 
 
24 
P50 suppression. The auditory P3b component is generated during active attention to 
rare deviant sounds within a stream of repetitive sounds. The chemotherapy-induced disruption 
of these active attentional processes may in fact have an earlier sensory basis in automatic 
information processing. One candidate source is sensory gating measured as suppression to the 
auditory P50 ERP component in a passive paired-click paradigm. Here, two brief auditory 
signals are presented 500 ms apart; the normal inhibitory response automatically activated to the 
first click is measured as a reduction in the P50 ERP amplitude to the second click (Clementz, 
Geyer, & Braff, 1997). P50 suppression is presumably a feature of normal sensory gating, 
instrumental in managing information overload (Nabor, Kathmann, & Enge, 1992). Indeed, P50 
suppression is significantly reduced in schizophrenia (Nashaat N. Boutros, Overall, & 
Zouridakis, 1991; Freedman et al., 1987)(Boutros, Zouridakis, & Overall, 1991; Freedman, 
Adler, Gerhardt, et al., 1987), a psychiatric syndrome marked by sensory flooding (McGhie & 
Chapman, 1961). 
P50 suppression has been traced in part to the inhibitory activity of α 7-nicotinic neurons 
in the CA3 region of hippocampus (Adler et al., 1998; Bickford-Wimer et al., 1990)(Adler, 
Olincy, Waldo, Harris et al., 1998; Bickford-Wimer, Nagamoto, Johnson et al., 1990), 
suggesting a role of sensory memory in the gating response. Noteworthy in this regard is the 
recent finding of a deficit in P50 suppression in Alzheimer’s dementia (Thomas, vom Berg, 
Rupp, et al., 2010). Other putative P50 generators include the thalamus (Jennifer Court et al., 
1999) (Court, Spurden, Lloyd et al., 1999; Hinman & Buchwald, 1983), auditory cortex (Godey, 
Schwartz, de Graaf, Chauvel, & Liegeois-Chauvel, 2001; Huang, Edgar, Thoma et al., 2003), 
and dorsolateral prefrontal cortex (Boutros, Gjini, Urbach, & Pflieger, 2011; Knight, Scabini, & 
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Woods, 1989). One analytic advantage of using the P50 gating paradigm is that the methods 
employed to study human subjects can be matched in studies of other animals. 
Gandal, Erlichman, Rudnick, and Siegal (2008) investigated in a mouse model the effects 
on P50 suppression of the breast cancer agents methotrexate and 5-fluorouracil. Mice injected 
with either low or high doses of the combined agents were compared electrophysiologically with 
placebo-injected control mice. Gandal et al. recorded from electrodes implanted in hippocampal 
CA3. This paradigm, reflecting whole brain electrical activity characteristically similar to human 
ERPs, revealed significant loss of suppression (defined as the ratio of P1 minus N1 amplitude of 
the second click to that of the first click) in both drug groups five weeks after treatment relative 
to controls. Importantly, chemotherapy had no effect on the amplitude of either the P1 or N1 
component to the first click, suggesting that perceptual encoding was preserved.  
Gandal et al. (2008) also implemented two behavioral tasks – novel object recognition 
(NOR) and contextual fear conditioning (CFC) – to clarify the role of hippocampal (memory) 
and amygdala (emotional) processing with respect to P50 sensory gating. In the NOR task 
chemotherapy-treated animals showed longer total exploration over both training and testing 
sessions in comparison to control animals. Gandal et al. suggested that chemotherapy-treated 
animals suffer an underlying memory deficit to novelty. In the CFC task, which is sensitive to 
hippocampus and amygdala function, chemotherapy-treated animals displayed significantly 
increased freezing ratios across time during the behavioral paradigm. Freezing ratios (CFC) were 
significantly correlated (r=0.57, p<0.02) with exploration time (NOR), demonstrating that 
performance in the two tasks were linked. The authors suggested that increased freezing ratios at 
initial training (CFC baseline) and decreased sensory gating are due to deficiencies in 
habituation. Overall, the results pointed to a hippocampus-based impairment in sensory 
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inhibition resulting from breast cancer treatment. One goal of the current study is to investigate 
the possible effects on P50 suppression of chemotherapy in breast cancer survivors several years 
after treatment.  
Mismatch Negativity Response. The results of several recent studies have suggested a 
functional link between P50 suppression and the mismatch negativity response (MMN), an ERP 
measure of the automatic detection of stimulus change (deviants) within an otherwise 
homogeneous stimulus environment (standards) that indexes the gating in of contextually 
important stimulus information (Naatenen, 1992). The MMN component has been successfully 
used to assess integrity of auditory memory in both healthy and clinical populations (Naatanen et 
al., 2011). Increases in P50 suppression co-vary with decreases in MMN responses in the elderly, 
patients with frontal lesions, and alcoholics, suggesting an interrelationship between the two 
processes. Moreover, both P50 suppression and MMN amplitude are impaired in schizophrenics 
and in their unaffected family members (Adler, Hoffer, Wiser, & Freedman, 1993; Adler, Hoffer, 
Griffith, Waldo, & Freedman, 1992)(Adler, Hoffer, Griffith, et al., 1992; Adler, Hoffer, Wiser, & 
Freedman, 1993; Jessen, Fries, Kucharski et al., 2001; Michie, Innes-Brown, Todd, & Jablensky, 
2002), implying that P50 and MMN are endophenotypes of preattentional deficits (Braff & 
Light, 2004).  
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Gating in and gating out. Both P50 suppression and MMIN amplitude can be measured 
in a single paradigm, known as the oddball paradigm. Here, participants are engaged in an 
attention-occupying task while standard and deviant auditory stimuli are presented. MMN is an 
increased negativity in the ERP wave to the deviant wave (relative to the standard) that peaks 
approximately 250 ms after stimulus onset. P50 suppression is seen as increased P50 (positive) 
amplitude to the deviant wave (relative to the standard). On one interpretation, increases in the 
amplitude of the MMN to deviant stimuli reflect pre-attentive recognition of novel stimuli, or 
gating in, whereas increases in P50 suppression to deviant stimuli reflect automatic exclusion of 
novelty, or gating out (Boutros, Torellob, Barkerb, et al., 1995; Boutros & Belger, 1999). In line 
with this interpretation, sensory gating in the MMN oddball paradigm can be operationally 
defined as: 1) the ratio of the amplitude of the response to the infrequent stimulus (deviant) 
divided by amplitude of the response to the frequent stimulus (standard), where higher ratios can 
either reflect stronger inhibition with repetition (gating out) or a stronger response to rare stimuli 
(gating in); and 2) as the differences between the deviant minus the standard (P50d), where 
higher values indicate more suppression. Investigating the P50 evoked response in a modified 
oddball paradigm, Boutros, Torello et al. (1995) proposed that with either interpretation of the 
P50 suppression response, higher standard/deviant ratios reflect a more active sensory gating 
mechanism subserved by distinct neuronal processes (i.e., gating in vs. gating out).  
Overlapping systems in frontal cortex are responsible in part for generating the P50 and 
MMN responses (Kisley, Noecker, & Guinther, 2004). Functional linkage implies a more general 
purpose gating system (Boutros, Torellob, Barkerb, et al., 1995). Ermutlu, Demiralp, and 
Karamursel (2007) employed an oddball paradigm in healthy participants to investigate 
interactions among the P50, N1, and MMN components. Using 1.5 s, 2.5 s, and 3.5 s 
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interstimulus intervals (ISIs), the authors found that the N1 component increased significantly 
with increasing ISIs for both standards and deviants, with N1 to deviants significantly larger than 
N1 to standards at 1.5 s ISI. In the 2.5 s ISI condition, MMN responses were significantly 
smaller, and amplitude of P50 suppression (P50d) significantly larger, than in the 1.5 s ISI or 3.5 
s ISI conditions, suggesting increased gating in and decreased gating out at this ISI. Furthermore, 
MMN amplitude increased with P50 suppression across ISIs. Ermutlu et al. concluded that the 
inhibition of repeated stimuli (P50d) aids the detection of deviant stimuli (MMN) (see also 
Kisley, Noecker, & Guinther, 2004; cf. Gjini, Arfken, & Boutros, 2011).  
Kisley et al (2004) investigated the functional significance of sensory gating by 
examining covariation among the P50, N100, and MMN components in an age-restricted (18-35) 
sample of healthy adults. The investigators used an abbreviated version of the Sensory Gating 
Inventory to characterize quantitatively each individuals’ daily experience regarding passive 
attention switching and associated perceptual phenomena in three different domains: perceptual 
modulation, distractibility, and over-inclusion.  
Kisley et al. (2004) found that P50 suppression was associated with participants’ ratings 
of perceptual modulation, whereas N100 suppression (N100S2 / N100S1) was associated with 
their ratings of over-inclusion. Further analysis revealed that P50 suppression was especially 
related to the rating items involving difficulties in excluding irrelevant stimuli (filtering), 
whereas N100 suppression was related to a heightened awareness of background sounds. No 
significant correlations were reported between ratings and MMN amplitude.  
Kisley et al. (2004) found no association between P50 and N100 suppression, supporting 
the notion that these components correspond to different processing systems. Similarly, there 
was no relationship between N100 suppression and MMN amplitude. However, the authors 
SENSORY INHIBITION AND MEMORY AFTER BREAST CANCER 
 
29 
found that P50 suppression and MMN amplitude correlated negatively: stronger P50 suppression 
during the paired-click paradigm was associated with weaker MMN amplitude in the oddball 
paradigm. The latter finding is consistent with a dual-use model, which may arise from either 
temporal or frontal cortical circuits believed to be involved in the generation of both P50 and 
MMN components.  
 
The Current Study 
Here, we measure both P50 suppression and MMN in two groups of participants 
(survivors and healthy controls) to assess the role of chemotherapy on the coordination between 
gating in and gating out processes. Within each group we explore whether the efficiency of 
sensory gating varied with age, to probe possible similarities between chemotherapy and normal 
aging in their effects on gating in and gating out (Pekkonen et al., 2005). We employed two 
separate measures of gating out: (1) the ratio of P50 amplitude to two clicks (paired-click 
paradigm) and (2) the ratio of P50 amplitude to standard and deviant tones (oddball paradigm).  
Methods 
Participants 
Eighteen women (40-66 years old), nine breast cancer survivors (average age =53.78 
years) and nine healthy controls (average age = 54.44 years), recruited from ads and referrals, 
volunteered to participate in the study. Each survivor was paired with an age-matched control 
participant (see Table 2); the average age of participants was equal across groups, t(16) = 0.16, 
ns. Standard audiometry was performed to screen participants for normal hearing, defined as 
pure tone sensitivity better than or equal to 20 dB HL bilaterally for octave frequencies between 
250 Hz and 8 kHz. All were right-hand dominant as determined by the Edinburgh handedness 
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survey (Oldfield, 1971). Exclusion criteria included: (1) metastasis or relapse; (2) history of or 
current neurological or primary psychiatric disorder; (3) head trauma; (4) alcohol or drug abuse; 
(5) lack of fluency in English. One further exclusion criterion for controls was previous history 
of cancer or treatment with chemotherapy. Inclusion criteria for survivors included: (1) diagnosis 
of invasive breast cancer; (2) treatment with standard-dose chemotherapy; (3) no cancer 
treatment except tamoxifen for two or more years; (4) currently disease free; (5) greater than 18 
years old when diagnosed. The nature of the procedures was explained fully, and informed 
consent was obtained from each participant. The Institutional Review Board of the City College 
of New York approved the protocol. 
Stimuli, apparatus, and procedure 
Each participant completed three blocks of trials: one block of the MMN oddball 
paradigm (800 trials) between two blocks of the P50 paradigm (150 trials each). The study was 
carried out in an electrically and acoustically shielded Industrial Acoustics Company (New 
York) chamber. The stimuli were delivered over Nova-40 headphones. Stimuli were created 
using Adobe Audition, digitized to eight bits at a sampling rate of 48 kHz. In both paradigms, 
participants were instructed to ignore the auditory stimuli and to watch a silent movie, as they sat 
in a comfortable chair at a distance of 60 cm from a Dell Model P1130 RGB computer monitor. 
Stimuli used in the P50 paradigm were 150 pairs of identical clicks presented binaurally 
at an intensity of 72 dB HL and a duration of .035 ms. Each pair was separated by an inter-
stimulus interval of 500 ms. The inter-trial interval varied randomly between 9 s and 10 s in 
rectangular distribution. Stimuli used in the MMN paradigm were 800 pure tones presented 
binaurally at an intensity of 72 dB HL and duration of 100 ms, including 10 ms rise/fall. Deviant 
tones (1030 Hz) appeared pseudorandomly within a stream of standard tones (1000 Hz); at least 
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two standards separated the deviants in the stream. Stimulus probability was 80% for standards 
and 20% for deviants. The inter-stimulus interval varied between 1080 ms and 1320 ms in 
rectangular distribution. 
Participants were given short breaks throughout testing. The entire experiment, including 
EEG preparation, lasted approximately three hours. 
EEG Recording 
Continuous recordings of the EEG were collected at a sampling rate of 512 Hz using a 
BioSemi Active-Two system in a high-density (160 electrodes) montage arranged in an elastic 
cap. Blinks and other eye movements were monitored by electrooculogram (EOG) from two 
electrode montages, one on the infra and supra-orbital ridges of the right eye (VEOG), the other 
on the outer canthi of each eye (HEOG). Fieldtrip ™ was used to process EEG data to perform 
automatic muscle artifact rejection (Oostenveld, Fries, Maris, & Schoffelen, 2011). To 
accumulate evidence of artifacts the Fieldtrip algorithm z-normalizes and averages time points 
across electrodes, based on calculations of the Hilbert envelope (amplitude of the signal) on each 
electrode over time and each electrode’s mean and standard deviation over samples. Trials 
contaminated by blinks or eye movements were removed using independent-components 
analysis (Blasiak et al., 2004); Jung et al., 1998). Prior to signal averaging, waveforms were 
inspected individually for movement artifacts; rejected channels from a trial were interpolated 
using a linear nearest-neighbor algorithm (Bastiaansen & Knosche, 2000). On average, 
approximately 25% of trials were rejected because of movement, eye, or jump artifacts.  
Sweep time in the paired-click paradigm was 450 ms, including a 50 ms pre-stimulus 
baseline; signal-averaged waveforms referenced to linked mastoids were digitally band-pass 
filtered between 6 and 50 Hz (de Wilde, Bour, Dingemans, Koelman, & Linszen, 2007). Peak 
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amplitude and peak latency of the P50 ERP component to each click were measured at each 
scalp location within a 40-80 ms post-onset search epoch. P50 suppression was measured as the 
ratio of P50 peaks to the two clicks (P50S2/P50S1). A second measure of P50 suppression was 
derived in the passive oddball task by comparing the ratio of P50 peaks to the standard and 
deviant tones (P50standard/P50deviant). S1 peak amplitude, measured as baseline to peak, was 
determined by implementing peakdet.m, a public domain Matlab function (Billauer, 2012). The 
function exploits the alternating nature of the derivatives along a user-defined threshold to 
robustly identify local maxima or minima (peaks or valleys) in a noisy vector. Peak and latency 
for S2 were determined in a similar manner, constrained to be within 10 ms of S1.  
Sweep time in the oddball paradigm was 1100 ms, including a 100 ms prestimulus 
baseline; signal-averaged waveforms referenced to the nasion were band-pass filtered between .1 
and 20 Hz. MMN was measured as the peak amplitude and peak latency of the difference wave 
(standard minus deviant waveforms) at each scalp location within a 175-250 ms post-onset 
search epoch. For ease of comparison, all analyses of ERP (P50 and MMN) amplitudes, 
including correlational analyses, were performed at the Cz electrode location. To identify the 
scalp topography of group differences in P50 suppression or MMN, we report cluster analyses 
(Oostenveld et al., 2011) conducted on P50 or MMN group contrasts, thus controlling for 
multiple comparisons. 
Dipole Source Analysis 
We employed Brain Electrical Source Analysis (BESA;Scherg & Von Cramon, 1986; 
Weisser R. et al., 2001) to isolate the relative contribution of four putative neural generators of 
the P50 suppression response: hippocampus (Rosburg et al., 2004), thalamus (Williams, 
Nuechterlein, Subotnik, & Yee, 2011), superior temporal gyrus (STG; Thoma et al., 2005), and 
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dorsolateral prefrontal cortex (DLPFC; Grunwald et al., 2003). Eight dipoles, seeded bilaterally, 
were fit as regional sources: hippocampus (right: 30.0, -17.3, -12.0; left: -30.0, -17.3, -12.0 with 
x, y, z coordinates in Talairach space), thalamus (right: 9.3778, -31.30, 8.7978; left: -9.3778, -
31.30, 8.7978), STG (right: 61.0, -27.0, 16.0603; left: -61.0, -27.0, 16.0603), and DLPFC (right: 
50.0, 39.0, 17.0; left: -50.0, 39.0, 17.0). 
The P50 peak was defined as the maximum of the regional source activity at the first 
orientation within a time interval identified individually for each participant and separately to 
each stimulus, S1 and S2. The P50 interval was determined by visual inspection to exclude the 
P30 and N40 components while falling within an epoch 40-80 ms after stimulus onset. We used 
a four-shell model, fixing the electrical conductivities of cerebrospinal fluid, skin, bone, and 
brain to 1.0, 0.33, 0.0042, and 0.33 S/m, respectively. The four dipole moments to each stimulus 
were then subjected to a mixed-model analysis of variance (ANOVA), with anatomical location 
(4 levels: thalamus, hippocampus, STG, DLPFC), hemisphere (2 levels: left, right), stimulus type 
(2 levels: S1, S2), and group (2 levels) as within-subject factors. All main effects and interactions 
reported as significant were reliable after Greenhouse-Geisser correction if appropriate 
(Greenhouse and Geisser, 1959). 
Results 
P50 suppression 
Figure 3 (left panels) depicts the grand averaged ERP waveforms evoked at Cz by each 
click in the breast cancer survivors (middle panel) and healthy age-matched controls (top panel). 
No differences between groups were found in the amplitude of either the P1 or N1 ERP 
components to the first click (p’s>.10). However, the breast cancer survivors showed 
significantly weaker P50 suppression than controls at this electrode location, t(8) = 2.51, p<.05. 
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The average suppression index (P50S2/P50S1) at Cz was .72 for survivors and .45 for controls, 
comparable to differences found between healthy controls and patients diagnosed with 
schizophrenia (Clementz et al., 1997) and Alzheimer’s disease (Thomas et al., 2010). Cluster 
analysis controlling for multiple comparisons revealed that the group differences predominated 
over central and parietal electrode sites in the right hemisphere (see Figure 3, bottom left panel). 
Table 2 summarizes the suppression index to each pair of age-matched participants, revealing 
consistently weaker suppression in cancer survivors compared with controls.  
As shown in the right panels of Figure 3, the group effect was replicated in the oddball 
measure of P50 suppression (P50standard/P50deviant), with significantly weaker suppression at Cz 
for survivors (.93) than controls (.81), t(8) = 2.48, p<.05. Cluster analysis of this measure (Figure 
3, bottom right panel) indicated significant clusters over left temporal locations. 
Dipole analysis of P50 suppression 
Figure 4 illustrates the average magnitude of dipole moments to S1 and S2 at each of the 
four bilateral neural structures thought to contribute to P50 suppression in the paired-click 
paradigm: hippocampus, thalamus, STG, and DLPFC. This model accounted for 89.69% of the 
variance in the control participants and 90.41% of variance in the survivors. ANOVA of dipole 
magnitudes yielded a significant main effect of location, F(3, 24) = 12.45, p<.001, MSe = 41.08, 
a main effect of stimulus type, F(1, 8) = 17.47, p<.01, MSe = 18.59 and, most important, a 
significant interaction of location, type, and group, F(3,24) = 3.71, p<.05, MSe = 3.29.  
As shown in Figure 4, the magnitude of dipole moments in the thalamus, STG, and 
DLPFC was comparable between groups. However, survivors showed significantly weaker 
dipole activity than controls in the hippocampus, across both hemispheres. Our finding with 
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survivors is reminiscent of that recently reported by Williams et al. (2011) on a group of young 
schizophrenics (average age = 27.6 years). 
Mismatch negativity 
Figure 5 depicts the average ERP at Cz to standard and deviant tones in the cancer 
survivors (left middle panel) and healthy controls (left top panel). MMN area is represented with 
shading in each panel. ERP difference waves (deviant minus standard) for each group appear in 
the bottom panel. There were no differences in the onset of the MMN component in the two 
groups, t(8) = .47, ns. However, the magnitude and duration of MMN were significantly weaker 
at Cz in the survivors than in the control participants, t(8) = 4.18, p<.01. Moreover, cluster 
analysis revealed that the difference between groups was widespread across scalp locations (see 
Figure 3, right panel). 
Correlational analyses 
Table 2 summarizes correlations of participants’ age with the three ERP measures: 
P50S2/P50S1, P50standard/P50deviant, and MMN. We found at Cz that P50S2/P50S1was associated 
with age in the control group (r = .63), with older participants revealing weaker P50 suppression. 
Importantly, this relationship was not observed in the survivor group (r = .08), suggesting that 
chemotherapy had disrupted effects of normal aging on sensory gating (Pekkonen et al., 2005). 
However, we found that the relationship between P50standard/P50deviant and age was roughly the 
same in survivors (r = .37) and controls (r = .59). Interestingly, P50S2/P50S1 and 
P50standard/P50deviant were associated positively in controls (r = .56), but negatively in 
survivors (r = -.43). MMN amplitude (greater amplitude = more negative voltage) was found to 
decline significantly with age (r = .46; controls, r = .54, survivors, r = 53). MMN and 
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P50standard/P50deviant were correlated positively in the oddball paradigm (r = .37; controls, r = .20, 
survivors, r = .24). 
  




A group of breast cancer survivors and a group of age-matched healthy control 
participants watched silent films while pairs of clicks or streams of tones were presented over 
headphones. The experiment revealed for the first time in survivors significant chemotherapy-
dependent deficits in processes of both sensory inhibition (as measured by P50 suppression) and 
sensory memory (as measured by MMN). The survivors exhibited a relatively weakened ability 
to inhibit redundant sensory stimulation, whether to the second of a pair of clicks or to a train of 
identical auditory tones. The scalp topography of group differences in P50 suppression differed 
by paradigm, peaking over the right hemisphere in the paired-click paradigm and over the left 
hemisphere in the oddball paradigm. Dipole source analysis localized the survivors’ loss of P50 
suppression to the hippocampus, with relative preservation of function in the gating out 
mechanisms of the frontal lobe and auditory cortex. Survivors also showed a diminution in the 
sensory memory processes needed to register novel or deviant information in an otherwise 
homogenous auditory environment. The fact that deficits in both gating in and gating out were 
observed within the same (oddball) paradigm indicates an especially strong linkage between 
these processes as modulated by chemotherapy agents. Nevertheless, correlational analyses 
suggested that the paired-click paradigm is particularly sensitive to the detrimental effects of 
chemotherapy on sensory gating; here, we found that the effects of normal aging on P50 
suppression seen in healthy controls were superseded by chemotherapy-related changes in an 
age-matched group of cancer survivors. Collectively, our findings suggest that cancer/cancer 
treatments are associated with a pervasive disruption of early, automatic mechanisms of sensory 
gating. 
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Relationships between sensory inhibition and sensory memory 
A central motivation of the current study was to extend to humans the results reported by 
Gandal et al. (2008) revealing a significant reduction in P50 suppression in a mouse model. As in 
their study, we found that the difference in P50 electrophysiological activity between 
chemotherapy and control groups was restricted to the second click; in both studies, 
chemotherapy left largely unaffected the P1 and N1 ERPs to the first click (see Figure 3), 
suggesting that in both mice and humans agents used to treat breast cancer leave untouched early 
stages of perceptual processing. Instead, these agents targeted processing of the repeated click, 
indicating that the disruption to stimulus processing from chemotherapy begins with a 
breakdown in the normal buildup of sensory inhibition to redundant information.  
The close correspondence in P50 suppression between chemotherapy-treated mice and 
human cancer survivors tested in the paired click paradigm suggests that breast cancer treatment 
is perhaps sufficient to damage sensory inhibition, although additional effects on cognitive 
function may arise from the cancer itself (Kesler et al., 2011; McDonald et al., 2012), radiation 
treatment, hormone replacement therapy used to treat the cancer (Falleti et al., 2005; Jenkins et 
al., 2004), or the emotional reactions to the cancer diagnosis or its treatment (Amir & Ramati, 
2002; Smith et al., 2011). 
To be sure, self-reports from survivors in the breast cancer community underscore the 
fact that cognitive loss from chemotherapy includes more than simply disruptions to sensory 
function, but also (and predominantly) poorer attention, memory, and executive functions 
(Schagen et al., 2006; Wefel et al., 2004). What is the relationship between the current findings 
and the types of functional loss typically reported by survivors? One hypothesis is that early 
sensory deficits trigger a chain reaction affecting later functions along the stream of cognitive 
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processes, thereby accounting for the broad range of deficits associated with chemobrain. 
Previous investigators have already pointed (in healthy participants) to a possible linkage in the 
processing chain between sensory inhibition and sensory memory, the former employed to 
minimize redundant information, the latter to flag non-redundant (novel) information (Ermutlu, 
Demiralp, & Karamursel, 2007). Our second goal in the current study was to probe whether these 
two types of gating are linked as dual consequences of chemotherapy. We found that both P50 
suppression and MMN amplitude were reduced in breast cancer survivors relative to controls, 
suggesting a connection between the inhibitory processes active 50 ms after stimulus onset and 
the comparison processes evident 150 ms later. We also found in the oddball paradigm a modest 
positive correlation (r = .37) between P50 suppression and MMN amplitude. What 
psychophysiological processes tie these two ERP components together in the context of 
chemotherapy treatment? Two possibilities present themselves. 
First, perhaps chemotherapy-induced damage to inhibitory mechanisms disrupts the 
quality of information handed off to later sensory memory mechanisms. On this account, 
chemotherapy’s harmful effects are limited to the neural generators driving P50 suppression, 
leaving intact those responsible for the MMN response. One downstream consequence of 
inefficient gating out – here, the failure to properly inhibit repeated (standard) events – is 
inadequate gating in, specifically, failure to readily detect novel (deviant) events in the 
environment (Ermutlu et al., 2007). Chemotherapy-induced loss of P50 inhibition could thus 
itself explain the drop in MMN amplitude seen in survivors. Variants on this account might also 
explain the associations between P50 suppression and MMN amplitude reported in other clinical 
populations, including individuals with schizophrenia or Alzheimer’s disease (Adler et al., 1993; 
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Adler et al., 1992; Jessen et al., 2001) Michie et al., 2002; but see Gjini et al., 2010; Turetsky et 
al., 2009). 
A second possibility is that chemotherapy damages neural structures common to gating in 
and gating out activities. Both P50 suppression and MMN responses tap stimulus memory 
processes: In the former, the evoked memory of a recent stimulus triggers an inhibitory response, 
whereas in the latter a response is evoked when the current stimulus deviates from recent 
memory. Both P50 suppression and MMN responses are disrupted when healthy participants are 
administered scopolamine (a muscarinic receptor antagonist), suggesting a common cholinergic 
pathway (Callaway, Halliday, Naylor, & Brandeis, 1991); Pekkonen et al., 2001). Finally, both 
responses are heavily dependent on neural generators localized to the temporal and frontal lobes, 
suggesting common pre-attentive auditory mechanisms (Giard et al., 1990; Godey et al., 2001; 
Knight et al., 1989a; Näätänen and Michie, 1979). On this second account, then, chemotherapy 
agents target the memory comparison mechanisms of the frontal or temporal lobes that subserve 
the two types of gating. As we discuss later, however, dipole analysis performed in the current 
study makes this account the less likely. 
Neurobiological basis of chemotherapy-induced cognitive impairment 
Animal models of cancer treatment commonly implicate the hippocampus in 
chemotherapy-induced cognitive impairments. Dietrich et al. (2006) reported that the therapeutic 
agents carmustine, cisplatin, and cytosine arabinoside disrupt neurogenesis of progenitor cells 
and oligodendrocytes in the dentate gyrus in vitro and in vivo. Seigers et al. (2008) demonstrated 
that the breast cancer agent methotrexate interfered in a dose dependent fashion with 
hippocampal cell proliferation. Gandal et al. (2008) linked the methotrexate-induced crippling of 
hippocampal cells with reductions in the P50 gating response. Other research teams have shown 
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poorer performance in rodents after administration of chemotherapy agents on various 
hippocampally-dependent cognitive tasks, including the Morris water-maze task (Winocour et 
al., 2006) and the fear avoidance task (Reiriz et al., 2006). 
By contrast, neuroimaging studies often identify activity in the frontal lobe as 
differentiating human cancer survivors from healthy controls. For example, Silverman et al. 
(2007) using [O-15] water PET found significantly greater metabolic output in inferior frontal 
gyrus in breast cancer survivors (5-10 years post chemotherapy) performing a short-term 
memory task compared with age- and education-matched control participants. The authors 
offered as one interpretation increased compensatory activity in survivors to cope with functional 
loss from chemotherapy (cf. McDonald et al., 2012). This view suggests that neuroimaging 
techniques tap the consequences of chemotherapy-induced neural damage, but perhaps not the 
actual sources. 
Results from the current study, conducted with humans, align closely with animal models 
of chemotherapy. As discussed earlier, previous evidence suggests that four different neural loci 
contribute to the human P50 suppression response: hippocampus, thalamus, DLPFC, and STG. 
The mouse model tested by Gandal et al. (2008) localized chemotherapy-dependent loss of P50 
suppression to hippocampal CA3 cells. Similarly, here dipole analysis of P50 suppression 
revealed that group differences in humans are confined to the hippocampus (see Figure 4). 
Activity in the STG and DLPFC, neural generators common to the P50 suppression and MMN 
responses, were roughly comparable between survivors and controls. 




The current study demonstrated that breast cancer patients treated with chemotherapy 
suffer sensory gating deficits similar to those found in accordance with animal models. Yet, 
certain methodological issues limit the generality of our conclusions. First, it is possible that 
effect sizes reported here were influenced by sample selection bias. In particular, perhaps the 
individuals that we recruited for our study agreed to participate precisely because they had begun 
to notice difficulties in performing everyday cognitive tasks. Indeed, several of our participants 
mentioned spontaneously their own cognitive struggles in the workplace. It is conceivable that 
such individuals represent only a minority of breast cancer survivors, thus yielding an elevated 
estimate of the true effect size. Of course, it remains a challenge for researchers to avoid this sort 
of bias in cancer and other forms of biomedical research, implying that the true effect size may 
be unknowable.  
Second, the sample size used in this study – nine individuals in each group – was 
somewhat smaller than the standard used in this field. Although our success in matching 
participants in the two groups in age strengthened the robustness of statistical analyses, the 
higher P50 suppression ratios and reductions in MMN amplitude we found must now be 
replicated in breast cancer patients using larger sample sizes, in depth neuropsychological 
assessments, and cognitive tests beyond those employed in the present study.  
Finally, although we were able to account for over 90% of the variance in our dipole 
source model, it is possible that our use of many brain sources (four bilateral sources, eight in 
total) ensured the excellent outcome. Performing additional analyses with four bilateral random 
sources might provide baseline evidence as to how likely we were to obtain these results. 
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Correlational analysis of ERP P50 suppression and P50 suppression using dipole sources could 
further our supposition that deficits are attributable to hippocampal activity.   
  




It is unlikely that a single mechanism can explain most of the major cognitive 
impairments observed in cancer patients following chemotherapy. While the analyses presented 
here point toward hippocampal sources of cognitive loss, clinical studies have demonstrated 
cancer-related cognitive impairment in non-hippocampal dependent tasks (Ahles et al., 2008). In 
addition, neuroimaging studies provide evidence for bilateral reductions in gray matter in frontal, 
temporal, cerebellar, thalamic, and cingulate brain region (Inagaki et al., 2007; McDonald et al., 
2010) as well as deficits in integrity in frontal, and temporal white matter tracts (Deprez et al., 
2012). The goal of future research is to explore further the constellation of factors that contribute 
to cancer-related cognitive impairments. 
Source Localization of MMN 
The current study performed source analysis solely on the P50 response. P50 suppression 
reflects only one stage of information processing that can be assessed in the auditory evoked 
response elicited in the paired click and oddball paradigm (Lijffijt et al., 2009). Perhaps the P50 
component, being a measure of pre-attentive automatic processing, would not reveal frontal 
differences in frontal activations. It is possible that early (N100) and late (P200) attentive 
processes, which depend more heavily on frontal (and other regional) processes, are also affected 
by cancer treatment. Boutros, Gjini, Urbach and Pflieger (2011) found that several prefrontal, 
cingulate, and parietal lobe region displayed stronger response suppression than primary auditory 
cortex when mapping the N100 response.  
Repeatedly, deficits in the MMN response, expressed as deficient auditory discrimination 
and orienting, have been used to assess objectively cognitive decline in clinical populations 
(Naatanen et al., 2011). The MMN receives bilateral contributions from the supra-temporal 
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plane, in addition to right-hemisphere frontal activity (Naatanen, Paavilainen, Rinne, & Alho, 
2007). It is recommended that future studies seek to source localize three separate components – 
N100, P200, and MMN – to identify possible temporo-frontal deficiency from cancer treatment. 
Stress and the Hippocampus 
Psychological stress reduces neurogenesis in the dentate gyrus (Wilson & Weber, 2013) 
and damages apical dendrites of pyramidal neurons located in the CA3 region of the 
hippocampus (Watanabe, Gould, & McEwen, 1992) . Stress activates the hypothalamic-pituitary-
adrenocortical (HPA) axis and elevates circulating glucocorticoids. Chronic exposure to stress or 
corticosteroids can inhibit proliferation and survival of new cells and induces depression-related 
behavior in animals. Interestingly, chemotherapy treatments similarly reduce hippocampal cell 
proliferation and neurogenesis, producing cognitive impairments in laboratory animals.(Christie 
et al., 2012). Moreover,Wilson and Weber (2013) found that daily restraint stress triggered 
suppression of cell proliferation in the dentate gyrus, independent of chemotherapy treatment. 
Future research should examine the interrelationships among stress and cancer treatments in 
cognitive decline. 
Recent animal studies suggest that stress may affect a region of hippocampus separate 
from that regulating cognition. The dorsal (septal) hippocampus is preferentially involved in 
cognitive processes while the ventral (temporal) hippocampus is involved in anxiety regulated 
behaviors and emotion (Bannerman et al., 2004; Tanti, Rainer, Minier, Surget, & Belzung, 
2012). For example, (Tanti et al., 2012) found that stress selectively disrupted cell proliferation 
and neurogenesis in the rodent ventral hippocampus, whereas environmental enrichment 
selectively increased neurogenesis in the dorsal hippocampus.  
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One measure of physiological response to stress is increases in inflammatory immune 
signals called cytokines. Evidence suggests that cognitive dysfunction following breast cancer 
chemotherapy may be mediated by the cytokines tumor necrosis factor-alpha (TNF-α) and 
interleukin-6 (IL-6). In animals, Terrando et al. (2010) found that increases in TNF-α after 
surgery induced peripheral and central inflammation, which led in turn to hippocampal-
dependent reductions of freezing in their contextual fear response. In humans, Kesler et al. 
(2012) found that breast cancer survivors displayed significantly elevated concentrations of  IL-6 
and TNF-α and that these elevations were associated with significant reductions in left 
hippocampal volumes and memory performance. The extent of harm of this inflammatory 
response is far reaching, with the regulatory functions of TNF-α and IL-6 actually promoting 
tumor inflammation and genesis (Grivennikov & Karin, 2011).  Conversely, breast cancer 
patients who undergo stress reduction interventions have reduced risk for breast cancer 
recurrence and death compared with patient controls (Andersen et al., 2008). Similarly, 
mitigation of co-occurring symptoms including stress, anxiety, hot flashes, depression, fatigue, 
and insomnia - either as a result of treatment side-effects or as a result of enduring the major 
medical threat that comes with a cancer diagnosis - improves memory and executive function in 
affected cancer patients (Carpenter et al., 2002; Desai et al., 2013; Reid-Arndt & Cox, 2012). 
Effective coping strategies have enabled patients to overcome side effects such as fatigue and 
cognitive impairment (Fitch, Mings, & Lee, 2008; Myers, 2012). 
Anxiety and negative affect in cancer patients are associated with changes in immune 
responses and upregulated expression of pro-inflammatory and metastasis-related genes (Antoni 
et al., 2012). Recent results reported by Grigsby et al. (2012) found that changes in blood 
inflammatory proteins may be important predictors of working memory and fine motor skills. 
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Behavioral interventions, such as cognitive-behavioral stress management (CBSM), reverse 
anxiety-related leukocyte transcriptional dynamics including downregulation of pro-
inflammatory and metastasis-related genes (Antoni et al., 2012).  
Exploration of the relationship of neuropsychological tests of long-term cognitive 
impairments indexed by the pre-attentive electrophysiological responses to risk factors such as 
stress, inflammation, sleep disturbance, and anemia is warranted. Extending this investigation 
using both neuropsychological tests and cognitive tasks that produce ERPs sensitive to attention 
will provide new information about the brain-behavior relationships in cancer-related 
impairments.





Our findings suggest that chemotherapies used to treat breast cancer in humans 
preferentially target hippocampal mechanisms of sensory inhibition. Probable damage to α7-
nicotinic cells in the CA3 subfield hinders buildup of inhibition to initial sensory input, yielding 
abnormally strong sensory activity to recurrent stimulation. Consequent sensory flooding triggers 
a cascade of attention and memory deficits further down the information processing line, 
including disruptions to gating in (MMN) and inhibitory control (executive function) functions. 
On this view, then, chemotherapy effectively accelerates cognitive aging (Ahles et al., 2012; see 
also Ahles and Saykin, 2007; Papazoglu and Mills, 1997) through disruption of hippocampally-
dependent memory functions (cf. J. Court et al., 2001). Increased compensatory activity in the 
frontal lobe (Ferguson et al., 2007; Silverman et al., 2007) may serve in a subgroup of cancer 
survivors to partially offset cognitive dysfunction from chemotherapy, which could account for 
instances of preserved performance on certain neuropsychological tests (Ahles et al., 2002; Tager 
et al., 2009). Survivors may nevertheless be acutely aware of loss, at least in higher cognitive 
functions, and a need for greater mental effort to compensate; hence, the consistent self-reports 
of cognitive impairment following chemotherapy (Berglund et al., 1991; Shilling and Jenkins, 
2007). If our account is accurate, ideal therapies for cognitive deficits after cancer and cancer 
related treatment would aim to restore the early inhibitory processes, such as those gauged by 
P50 suppression.  
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 Table 1 
Review of Animal Studies of Chemotherapy-Related impairments. 
 
Adapted from Seigers et al. (2011) 





Alkylating agents         
 Konat Cyclophosphamide + 
doxorubicin 
Passive avoidance + 
open field 
Impaired passive avoidance 
learning No effect on anxiety 
behavior 
 Cyclophosphamide or 5-
fluorouracil 
MWM + Stone 14-unit 
T-maze 
No impairment Transient improvement in 
MWM and Stone 14-unit T-
maze seven to nine weeks 
post treatment 
Macleod Cyclophosphamide + 
doxorubicin 
Cued and contextual 
fear conditioning 
Impaired contextual fear 
memory No effect on cued-fear or 
acquisition of fear response 
 Mondie thioTEPA 
NOR + OLR 
Impairment in NOR and 
OLR 
No effect on depressive 
behavior 




No effect on anxiety 
behavior 
 Yang Cyclophosphamide Passive avoidance + 
NOR 





        
 Fardell Oxaliplatin + 5-
fluorouracil 
MWM + NOR + fear 
conditioning 
Impairment in MWM, NOR 
and contextual fear memory 
No impairment in cued-fear 
memory 
Antimetabolites         
 Elbeltagy 5-Fluorouracil 
Fear conditioning + 
OLR 
Impairment in recall of fear 
conditioning memory and 
OLR 
  
 Foley Methotrexate + 5-
fluorouracil 
Operant conditioning Combined MTX + 5-FU 
impair acquisition and 
retrieval of an operant 
response 
No impairment due to 
MTX5-FU failed to impair 
operant conditioning except 
at high doses 
 Li Cytosine arabinoside MWM Impairment in remote recall 
of MWM 
No impairment in MWM 
learning or recent recall 
 Li Methotrexate NOR + OLR Impaired OLR No impairment in NOR + 
open field activity 




avoidance learning and 
memory 
No effect on anxiety 
behavior 
 Mustafa 5-Fluorouracil OLR Subtle impairment in OLR 
  
 Seigers Methotrexate MWM + NOR + 
contextual fear 
conditioning 
Impairment in MWM and 
NOR after MTXWhen 
trained prior to MTX 
treatment, impairment in 
MWM and fear 
conditioning memory 
  





Review of Animal Studies of Chemotherapy-Related impairments. 
 









Methotrexate Passive avoidance task Impaired passive 
avoidance learning 
  




No impairment in either 
appetitive or aversive 
conditioning 
  
 Yanovski Methotreate Conditioned emotional 








 Winocur Methotrexate + 5-
fluorouracil 





Impairment in spatial 
MWM, NMTS and 
dNMTS 
No impairment in cued 




    
  
  
 Liedke Doxorubicin Inhibitory avoidance 
conditioning 
Impairment of memory 
retention 
  






    
 Boyette-Davis 
Paclitaxel 
Five choice serial 
reaction time task 
No impairment   












1  41 40  1.00 0.43 
2  44 47  0.83 0.04 
3  46 47  0.66 0.36 
4  53 51  0.20 0.46 
5  55 55  0.74 0.34 
6  60 60  0.67 0.43 
7  59 60  0.78 0.73 
8  61 64  0.59 0.61 
9  65 66  1.00 0.64 
       
Average  53.78 54.44  0.72 0.45 
 
Table 2 














Correlation with participant age of P50 suppression (paired-click and oddball paradigms) and 
MMN indices, separately for healthy controls and breast cancer survivors. 
  
 P50S2/P50S1  P50standard/P50deviant  MMN 
      
Controls 0.63  0.37  0.46 
Survivors 0.08  0.59  0.54 
 




Figure 1. Factors that affect assessment of cognitive changes induced by drugs. 
Adapted from: (Minisini et al., 2004) 





Figure 2. Postulated mechanisms of chemotherapy-associated cognitive changes. 























Figure 3. Grand Average ERPs and Significant Clusters of P50 Supression 
Grand averaged ERP waveforms evoked at Cz by each click (S1 and S2) in the paired-click 
paradigm (left panels) and each tone (standard and deviant) in the oddball paradigm (right 
panels), separately for breast cancer survivors (middle panels) and healthy age-matched 
controls (top panels). Cluster analysis controlling for multiple comparisons revealed that the 
group differences over central and parietal electrode sites in the right hemisphere in the paired-
click paradigm (bottom left panel) and over left temporal locations in the oddball paradigm 
(bottom right panel). 
 


























Hippocampal loss of P50 
suppression in survivors
Figure 4. Average magnitude of dipole moments in paired-click paradigm by brain region 
Average magnitude of dipole moments to S1 and S2 in the paired-click paradigm for each group 
at each of four bilateral neural structures: hippocampus, thalamus, STG, and DLPFC. 
 
  





Figure 5. Grand Average MMN at CZ with Significant Clusters   
Average ERP at Cz to standard and deviant tones in cancer survivors (left middle panel) and 
healthy controls (left top panel). MMN area is represented with shading in each panel. Bottom 
panel: ERP difference waves (deviant minus standard) for each group. Right panel: Cluster 
analysis revealed that the difference between groups was widespread across scalp locations. 
 
 
